Global Cord Blood (NYSE:CORBF – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Global Cord Blood and Mangoceuticals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Global Cord Blood | 0 | 0 | 0 | 0 | N/A |
Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
Volatility & Risk
Valuation and Earnings
This table compares Global Cord Blood and Mangoceuticals’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Global Cord Blood | $196.12 million | N/A | $79.04 million | N/A | N/A |
Mangoceuticals | $730,000.00 | 10.21 | -$9.21 million | N/A | N/A |
Global Cord Blood has higher revenue and earnings than Mangoceuticals.
Institutional & Insider Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 39.3% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Global Cord Blood and Mangoceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Global Cord Blood | N/A | N/A | N/A |
Mangoceuticals | -1,068.72% | -864.10% | -577.68% |
Summary
Global Cord Blood beats Mangoceuticals on 5 of the 8 factors compared between the two stocks.
About Global Cord Blood
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.